OtherHead and neck cancers

Interaction between Tobacco and Alcohol Use and the Risk of Head and Neck Cancer: Pooled Analysis in the International Head and Neck Cancer Epidemiology Consortium

Cancer Epidemiology, Biomarkers & Prevention · 200911,221 cases (patients) and 16,168 controls
Hashibe M, Brennan P, Chuang Sc, Boccia S, Castellsague X, Chen C, et al. Cancer Epidemiology, Biomarkers & Prevention. 2009. 18:541-550
Study type
Other
Study name
INHANCE
Design
Pooled analysis of individual-level data from 17 European and American case-control studies in the International Head and Neck Cancer Epidemiology (INHANCE) Consortium
Sample size
11,221 cases (patients) and 16,168 controls
Source
Cancer Epidemiology, Biomarkers & Prevention · 2009

In plain words

This research looked at data from more than 11 thousand people with head and neck cancer and more than 16 thousand healthy people. The results showed that using cigarettes or other tobacco together with alcohol raises the risk of this cancer far more than their separate effects added together. However, a considerable share of these cancers, especially in women, in young people and in cancer of the mouth, is not linked to tobacco or alcohol.

Key results

2.15
Multiplicative interaction of tobacco and alcohol (psi)
95% CI 1.53–3.04; joint effect more than multiplicative
72%
Population attributable risk (PAR) for tobacco or alcohol
95% CI 61–79%
4% / 33% / 35%
Share of PAR: alcohol alone / tobacco alone / tobacco and alcohol combined
Oral cavity 64%, pharynx 72%, larynx 89%
Overall PAR by subsite
74% in men vs 57% in women
Overall PAR by sex
33% in cases under 45 years vs 73% in cases over 60 years
Overall PAR by age
Europe 84%, North America 51%, Latin America 83%
Overall PAR by region

Treatment arms and regimens

1Cases (patients with head and neck cancer)

This is an observational study with no intervention. 11,221 patients with head and neck cancer were studied. Dose details in the full text.

2Controls

16,168 controls, no intervention. Dose details in the full text.

Source of the regimen details: Abstract of the paper

Doses are given for the information of specialists, as in this study’s protocol, and are not a prescription. Every drug must be prescribed by the treating physician for the individual patient.

Study population

Patients with head and neck cancer and controls from 17 European and American case-control studies participating in the INHANCE consortium. Details of each study's inclusion criteria are not given in the abstract.

Endpoints

Estimation of the multiplicative interaction parameter (psi) between tobacco and alcohol use and of the population attributable risk (PAR) for head and neck cancer, by tumour subsite, sex, age and geographical region.

Safety and side effects

This is an observational study and no safety or treatment-related adverse-event data are reported.

Clinical significance and place in guidelines

This study provides strong epidemiological evidence for the importance of prevention, i.e. avoiding tobacco and alcohol, in reducing the burden of head and neck cancer, and shows that the effect of combined use is more than multiplicative. It also shows that in women, younger patients and oral cavity cancer, other risk factors play a role too. This is a case-control study, not a treatment guideline; the status of clinical recommendations should be checked in authoritative guidelines.

Limitations

Based on the abstract: the design is case-control and the included studies used different methods. Other limitations should be checked in the full text.

This summary was prepared by the editorial team from the published paper; the original paper is the final reference. Read the original abstract on PubMed.